Examining the influence of cooperative play on decision making in emerging adults with a history of suicidal behavior.
Summary
Why are we doing this study?
We want to know if cooperation during social games influences performance on cognitive tests.
We have chosen tests that are important in identifying risk for suicidal thoughts and behaviors. As such, our findings might help us to develop novel suicide prevention strategies.
What would I do?
Participants will be asked to tell us about their mental health. They will also be asked about their suicidal thoughts and behaviors. Participants will then play computer games that measure cognitive function.
How long is the experiment?
2 sessions. Total time of about 5-hours.
Optional: Third session 2-weeks later [additional 1.5-2 hours].
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 16 to 24
Inclusion criteria:
1. Age 16-24 years
2. Any gender
3. At least 2 previous suicide attempts
4. Capable of providing informed consent
5. Able to have parent/guardian supervision for at least 24 hours after the experiment
6. Can refrain from taking stimulant medications for at least 48 hours
7. Have not taken "as needed" psychiatric medication for anxiety or agitation in the past 48 hours (daily medication for depression and anxiety are okay)
Exclusion criteria:
1. Motor disability that prevents computerized testing
2. Colour blindness
3. Previously played Cyberball
5. Currently have suicidal intent
6. Attempted suicide within the past month
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
If you are interested in participating in this study, please email Maya Sohn at maya.sohn@ucalgary.ca
Principal investigator:
Alexander McGirr
Clinical trial:
No
REB-ID:
REB21-1915